The effect of 0.12% unoprostone isopropyl (Rescula) on intraocular pressure in normotensive dogs

Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound appr oved for treatment of glaucoma in humans. It is commercially available in J apan, and is undergoing clinical testing elsewhere. The aim of this study w as to evaluate the effect of Rescula on intraocular pressure (IOP) in normo tensive dogs. After establishing a baseline diurnal IOP curve, six dogs wer e unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupi l size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and longlasting decrease in IOP, from 20.49 +/- 2.02 mm Hg in control eyes to 15.49 +/- 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficaci ous in treatment of canine glaucoma.